Time to announce a partnership23 Jan 2026 11:36
BREAKING NEWS - Personalized mRNA cancer vaccine cuts melanoma recurrence risk by 49% at 5 year
Merck and Modemna have just reported 5-year followrup data from a study combining intismeran autogene (mRNA-4157) with KEYTRUDAO in patients with highrrisk melanoma.
Patients with resected stage II/IV melanoma face a very high risk of recurrence.
Checkpoint inhibitors have improved outcomes - but relapse still occurs in a substantial proportion of patients.
Hence this more personalized approach - mRNA neoantigen vaccine t checkpoint inhibition
Intismeran autogene is an individualized mRNA neoantigen therapy, designed using each patient's tumor mutational signature to train a precise, tumor-specific T-cell nesponse.
These are the results from the Phase 26 KEYNOTE-942 study 49%
reduction in risk of recurrence or death vs KEYTRUDA alone Sustained recurrence-free survival at a median 5-year followrup Safety profile consistent with prior analyses
A Phase 3 adiuvant melanoma trial is fully enrolled, with eight additional Phase 2/13 studies underway across multiple tumor types.